Stoke Therapeutics (STOK) Competitors

$31.36 -0.34 (-1.07%)

Closing price 04:00 PM Eastern

Extended Trading

$31.87 +0.51 (+1.63%)

As of 05:17 PM Eastern

STOK vs. PCVX, CYTK, KRYS, NUVL, and IBRX

Should you buy Stoke Therapeutics stock or one of its competitors? MarketBeat compares Stoke Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Stoke Therapeutics include Vaxcyte (PCVX), Cytokinetics (CYTK), Krystal Biotech (KRYS), Nuvalent (NUVL), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.

How does Stoke Therapeutics compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Stoke Therapeutics (NASDAQ:STOK) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, Stoke Therapeutics had 15 more articles in the media than Vaxcyte. MarketBeat recorded 21 mentions for Stoke Therapeutics and 6 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.99 beat Stoke Therapeutics' score of 0.37 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stoke Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

96.8% of Vaxcyte shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by company insiders. Comparatively, 9.5% of Stoke Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Vaxcyte presently has a consensus price target of $86.00, indicating a potential upside of 60.66%. Stoke Therapeutics has a consensus price target of $41.83, indicating a potential upside of 33.40%. Given Vaxcyte's higher possible upside, equities research analysts plainly believe Vaxcyte is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Vaxcyte has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -529.20%. Vaxcyte's return on equity of -32.51% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Stoke Therapeutics	-529.20%	-48.84%	-42.27%

Vaxcyte has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Stoke Therapeutics has higher revenue and earnings than Vaxcyte. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Stoke Therapeutics	$32.08M	60.88	-$6.89M	-$2.81	N/A

Summary

Vaxcyte beats Stoke Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Stoke Therapeutics compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Stoke Therapeutics (NASDAQ:STOK) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Cytokinetics currently has a consensus price target of $98.55, indicating a potential upside of 25.32%. Stoke Therapeutics has a consensus price target of $41.83, indicating a potential upside of 33.40%. Given Stoke Therapeutics' higher probable upside, analysts plainly believe Stoke Therapeutics is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.82
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Stoke Therapeutics has lower revenue, but higher earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	111.14	-$784.96M	-$6.84	N/A
Stoke Therapeutics	$32.08M	60.88	-$6.89M	-$2.81	N/A

In the previous week, Cytokinetics had 8 more articles in the media than Stoke Therapeutics. MarketBeat recorded 29 mentions for Cytokinetics and 21 mentions for Stoke Therapeutics. Cytokinetics' average media sentiment score of 0.46 beat Stoke Therapeutics' score of 0.37 indicating that Cytokinetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	5 Very Positive mention(s)	0 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Stoke Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Cytokinetics has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

Stoke Therapeutics has a net margin of -529.20% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Stoke Therapeutics	-529.20%	-48.84%	-42.27%

Summary

Cytokinetics beats Stoke Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Stoke Therapeutics compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Stoke Therapeutics (NASDAQ:STOK) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

Krystal Biotech presently has a consensus price target of $324.11, indicating a potential upside of 2.47%. Stoke Therapeutics has a consensus price target of $41.83, indicating a potential upside of 33.40%. Given Stoke Therapeutics' higher possible upside, analysts clearly believe Stoke Therapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Stoke Therapeutics had 10 more articles in the media than Krystal Biotech. MarketBeat recorded 21 mentions for Stoke Therapeutics and 11 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.72 beat Stoke Therapeutics' score of 0.37 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stoke Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

86.3% of Krystal Biotech shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 9.5% of Stoke Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Krystal Biotech has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Krystal Biotech has higher revenue and earnings than Stoke Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$417.30M	22.34	$204.83M	$7.48	42.29
Stoke Therapeutics	$32.08M	60.88	-$6.89M	-$2.81	N/A

Krystal Biotech has a net margin of 53.92% compared to Stoke Therapeutics' net margin of -529.20%. Krystal Biotech's return on equity of 19.25% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Stoke Therapeutics	-529.20%	-48.84%	-42.27%

Summary

Krystal Biotech beats Stoke Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Stoke Therapeutics compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and Stoke Therapeutics (NASDAQ:STOK) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

Nuvalent presently has a consensus price target of $137.25, indicating a potential upside of 31.45%. Stoke Therapeutics has a consensus price target of $41.83, indicating a potential upside of 33.40%. Given Stoke Therapeutics' higher possible upside, analysts clearly believe Stoke Therapeutics is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.88
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Stoke Therapeutics had 5 more articles in the media than Nuvalent. MarketBeat recorded 21 mentions for Stoke Therapeutics and 16 mentions for Nuvalent. Stoke Therapeutics' average media sentiment score of 0.37 beat Nuvalent's score of 0.19 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Stoke Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Nuvalent has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

97.3% of Nuvalent shares are held by institutional investors. 5.0% of Nuvalent shares are held by company insiders. Comparatively, 9.5% of Stoke Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Stoke Therapeutics has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Stoke Therapeutics	$32.08M	60.88	-$6.89M	-$2.81	N/A

Nuvalent has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -529.20%. Nuvalent's return on equity of -40.11% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Stoke Therapeutics	-529.20%	-48.84%	-42.27%

Summary

Stoke Therapeutics beats Nuvalent on 9 of the 15 factors compared between the two stocks.

How does Stoke Therapeutics compare to ImmunityBio?

Stoke Therapeutics (NASDAQ:STOK) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

Stoke Therapeutics has a net margin of -529.20% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-529.20%	-48.84%	-42.27%
ImmunityBio	-606.15%	N/A	-59.53%

In the previous week, ImmunityBio had 33 more articles in the media than Stoke Therapeutics. MarketBeat recorded 54 mentions for ImmunityBio and 21 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 0.37 beat ImmunityBio's score of 0.12 indicating that Stoke Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
ImmunityBio	6 Very Positive mention(s)	2 Positive mention(s)	36 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Stoke Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market.

Stoke Therapeutics has higher earnings, but lower revenue than ImmunityBio. Stoke Therapeutics is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$32.08M	60.88	-$6.89M	-$2.81	N/A
ImmunityBio	$113.29M	75.35	-$351.40M	-$0.85	N/A

8.6% of ImmunityBio shares are owned by institutional investors. 9.5% of Stoke Therapeutics shares are owned by insiders. Comparatively, 69.5% of ImmunityBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Stoke Therapeutics currently has a consensus target price of $41.83, suggesting a potential upside of 33.40%. ImmunityBio has a consensus target price of $14.20, suggesting a potential upside of 74.23%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts clearly believe ImmunityBio is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

ImmunityBio beats Stoke Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Stoke Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STOK vs. The Competition

Export

Metric	Stoke Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.95B	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-11.16	18.81	20.87	25.58
Price / Sales	60.88	181.67	521.63	63.56
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	4.95	6.74	9.86	6.70
Net Income	-$6.89M	$24.11M	$3.55B	$333.77M
7 Day Performance	-4.36%	0.07%	-0.32%	0.45%
1 Month Performance	-12.55%	0.84%	1.34%	4.06%
1 Year Performance	248.83%	78.10%	41.03%	36.21%

Stoke Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STOK Stoke Therapeutics	2.3974 of 5 stars	$31.36 -1.1%	$41.83 +33.4%	+255.0%	$1.95B	$32.08M	N/A	100	Earnings Report Analyst Forecast Analyst Revision
PCVX Vaxcyte	2.9421 of 5 stars	$58.49 +2.7%	$86.00 +47.0%	+80.5%	$8.22B	N/A	N/A	160	Options Volume
CYTK Cytokinetics	2.8728 of 5 stars	$66.05 +4.3%	$90.55 +37.1%	+152.3%	$7.87B	$88.04M	N/A	250	Trending News Analyst Forecast Options Volume Analyst Revision
KRYS Krystal Biotech	2.8274 of 5 stars	$284.93 +7.1%	$326.25 +14.5%	+132.3%	$7.83B	$389.13M	41.60	210	High Trading Volume
NUVL Nuvalent	2.9068 of 5 stars	$102.62 +3.6%	$137.25 +33.7%	+47.3%	$7.79B	N/A	N/A	40	Trending News Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STOK) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stoke Therapeutics (STOK) Competitors

STOK vs. PCVX, CYTK, KRYS, NUVL, and IBRX

How does Stoke Therapeutics compare to Vaxcyte?

Summary

How does Stoke Therapeutics compare to Cytokinetics?

Summary

How does Stoke Therapeutics compare to Krystal Biotech?

Summary

How does Stoke Therapeutics compare to Nuvalent?

Summary

How does Stoke Therapeutics compare to ImmunityBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK vs. The Competition

Stoke Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Stoke Therapeutics (STOK) Competitors

STOK vs. PCVX, CYTK, KRYS, NUVL, and IBRX

How does Stoke Therapeutics compare to Vaxcyte?

Does the media refer more to PCVX or STOK?

Do insiders & institutionals hold more shares of PCVX or STOK?

Do analysts prefer PCVX or STOK?

Is PCVX or STOK more profitable?

Which has more risk and volatility, PCVX or STOK?

Which has preferable earnings & valuation, PCVX or STOK?

Summary

How does Stoke Therapeutics compare to Cytokinetics?

Do analysts rate CYTK or STOK?

Which has preferable earnings & valuation, CYTK or STOK?

Does the media prefer CYTK or STOK?

Which has more risk and volatility, CYTK or STOK?

Is CYTK or STOK more profitable?

Summary

How does Stoke Therapeutics compare to Krystal Biotech?

Do analysts prefer KRYS or STOK?

Does the media refer more to KRYS or STOK?

Do insiders & institutionals believe in KRYS or STOK?

Which has more volatility and risk, KRYS or STOK?

Which has better valuation and earnings, KRYS or STOK?

Is KRYS or STOK more profitable?

Summary

How does Stoke Therapeutics compare to Nuvalent?

Do analysts prefer NUVL or STOK?

Does the media refer more to NUVL or STOK?

Which has more volatility and risk, NUVL or STOK?

Do insiders & institutionals believe in NUVL or STOK?

Which has better valuation and earnings, NUVL or STOK?

Is NUVL or STOK more profitable?

Summary

How does Stoke Therapeutics compare to ImmunityBio?

Is STOK or IBRX more profitable?

Does the media prefer STOK or IBRX?

Which has more risk and volatility, STOK or IBRX?

Which has higher earnings and valuation, STOK or IBRX?

Do insiders and institutionals have more ownership in STOK or IBRX?

Do analysts recommend STOK or IBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK vs. The Competition

Stoke Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools